- Report
- August 2024
- 147 Pages
Global
From €2691EUR$2,999USD£2,316GBP
- Report
- May 2024
- 134 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- May 2024
- 129 Pages
Global
From €5831EUR$6,499USD£5,019GBP
- Report
- May 2023
- 143 Pages
Global
From €2019EUR$2,250USD£1,738GBP
- Report
- December 2023
- 100 Pages
Global
From €5339EUR$5,950USD£4,595GBP
- Report
- May 2021
- 50 Pages
China
From €2333EUR$2,600USD£2,008GBP
- Report
- October 2023
- 181 Pages
Global
From €4038EUR$4,500USD£3,475GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €449EUR$500USD£386GBP
Vfend (voriconazole) is an antifungal medication used to treat a variety of fungal infections. It is used to treat infections caused by Candida, Aspergillus, and other fungi. It is also used to prevent fungal infections in people who are at high risk of developing them. Vfend is a member of the triazole class of antifungal drugs, which work by inhibiting the growth of fungi.
Vfend is used to treat a variety of fungal infections, including those of the skin, nails, and mucous membranes. It is also used to treat fungal infections of the lungs, urinary tract, and other organs. Vfend is also used to prevent fungal infections in people who are at high risk of developing them, such as those with weakened immune systems.
The Vfend market is a subset of the larger Infectious Diseases Drugs market. It is composed of pharmaceutical companies that manufacture and market antifungal medications, such as Vfend. These companies develop and produce antifungal medications, as well as provide support services such as clinical trials and marketing.
Some companies in the Vfend market include Pfizer, Merck, Novartis, and AstraZeneca. Show Less Read more